GI: Metastatic Neuroendocrine Carcinoma of the Pancreas
Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
1. Histologic documentation of well differentiated or moderately differentiated neuroendocrine tumor from either a primary or metastatic site. Must have either histologic documentation of a pancreatic primary site, or clinical evidence of a pancreatic neuroendocrine primary tumor as determined by the treating physician.
2. Measurable or nonmeasureable disease.
Please contact Tricia Montgomery, RN for additional inclusion/exclusion criteria.